The HDAC1 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HT29 colorectal adenocarcinoma cell line. This loss-of-function model is designed for the study of histone deacetylase 1 (HDAC1) and its roles in epigenetic regulation, signal transduction, and tumor biology. The polyclonal nature of the knockout population preserves cellular heterogeneity, enabling investigations that more closely mirror the complexity of tumor environments versus clonal derivatives.
HT29 cells are a well-characterized epithelial cell line isolated from a primary colorectal adenocarcinoma. This model is widely employed in cancer research due to its ability to form tumors in vivo, its distinct mutational profile??including mutations in APC, TP53, and BRAF??and its responsiveness to a variety of therapeutic agents. HT29 cells are commonly used to dissect the molecular mechanisms underlying colorectal carcinogenesis, to evaluate drug efficacy, and to study signaling pathways such as Wnt/??-catenin, which is constitutively active in these cells.
HDAC1 is a class I histone deacetylase that removes acetyl groups from histones H3 and H4, promoting chromatin compaction and transcriptional repression. It forms complexes with corepressors SIN3A, MTA1/2, NCOR1/2, SAP30, Rb, and YY1, and is regulated by upstream kinases CK2 and PKC, as well as transcription factors E2F1, SP1, MYC, and STAT3. HDAC1 silences tumor suppressor genes including CDKN1A (p21) and BAX, while modulating CCND1 and p53. Through these interactions, HDAC1 coordinates cell proliferation, apoptosis, and differentiation in response to mitogenic and stress signals.
In HT29 colorectal adenocarcinoma cells, HDAC1 knockout eliminates class I HDAC activity, causing histone hyperacetylation and derepression of CDKN1A and BAX, thereby impairing cell cycle progression and enhancing apoptosis. This is particularly relevant as HDAC1 is often overexpressed in colorectal cancer. The polyclonal knockout population allows study of heterogeneous cellular responses to HDAC1 loss, providing insight into signaling crosstalk with the Wnt/??-catenin, Rb/E2F, and p53 pathways.
This product supports a wide array of experimental workflows, including Western blotting and RT-qPCR for expression analysis, ChIP-qPCR for histone modification profiling, cell proliferation and apoptosis assays, flow cytometry, and RNA-seq. Applications span epigenetic regulation, cancer biology, drug target validation, and colorectal cancer modeling, with particular utility in HDAC inhibitor studies and gene expression profiling. For further technical guidance, please contact Ascent Research.
